Naltrexone Modification of Drinking Effects in a Subacute Treatment and Bar-Lab Paradigm: Influence of OPRM1 and Dopamine Transporter (SLC6A3) Genes
Alcoholism: Clinical and Experimental Research,  Clinical Article

Anton RF et al. – This study does not support a salient role for the opioid receptor (OPRM1) asp40 alone in predicting drinking or naltrexone effects. However, although exploratory and in need of replication, it introduces the possibility that epistasis between the OPRM1 gene and dopamine transporter gene might need to be taken into account when examining differential genetic response to alcohol or medication treatment, especially in early–stage alcoholics.

Methods
  • Two hundred and sixty-five nontreatment-seeking individuals with alcohol dependence were genotyped a priori for the OPRM1 asn40asp SNP and post hoc for DAT (SLC6A3) 9 and 10 VNTRs.
  • Asp40 carriers (n = 43) and matched asn40 homozygotes (n = 40) were randomized to naltrexone or placebo for 7 days before receiving a priming drink and limited-access alcohol consumption in a bar-lab setting.
  • Effects of genotypes on natural drinking as well as drinking, alcohol effects, and response to naltrexone in the bar-lab setting were examined by genotype.

Results
  • There were no significant main effects of naltrexone or OPRM1 genotype, or any medication by OPRM1 interaction, on drinking variables.
  • However, in individuals who had at least one DAT 9 VNTR, and who were also OPRM1 asn40 homozygotes, naltrexone reduced drinks/d consumed under natural conditions (p = 0.006), but not in the bar-lab.
  • OPRM1 asn40 homozygotes (p = 0.028) and DAT 9 VNTR carriers (p = 0.032) had more stimulation to alcohol after the priming drink.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

1 Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up Psychiatry Research, December 3, 2014    Clinical Article

2 Are antidepressants equally effective in the long-term treatment of major depressive disorder? Human Psychopharmacology: Clinical and Experimental, December 8, 2014    Clinical Article

3 Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials Journal of Psychopharmacology, December 2, 2014    Clinical Article

4 Venlafaxine versus applied relaxation for generalized anxiety disorder: A randomized controlled study on clinical and electrophysiological outcomes Psychiatric Quarterly, December 19, 2014    Clinical Article

5 Nitrous oxide for treatment-resistant major depression: A proof-of-concept trial Biological Psychiatry, December 24, 2014    Clinical Article

6 Weight gain and associated factors in patients using newer antidepressant drugs General Hospital Psychiatry, December 4, 2014    Clinical Article

7 Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: A randomized, double-blind, placebo-controlled trial International Clinical Psychopharmacology, December 23, 2014    Clinical Article

8 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

9 Rational-emotive and cognitive-behavior therapy (REBT/CBT) versus pharmacotherapy versus REBT/CBT plus pharmacotherapy in the treatment of major depressive disorder in youth: A randomized clinical trial Psychiatry Research, December 15, 2014    Clinical Article

10 Theta-burst stimulation: A new form of TMS treatment for depression? Depression and Anxiety, December 22, 2014    Clinical Article

11 The impact of telephone versus e-mail therapist guidance on treatment outcomes, therapeutic alliance and treatment engagement in Internet-delivered CBT for depression: A randomised pilot trial Internet Interventions, December 12, 2014    Clinical Article

12 Maternal thyroid autoantibody and elevated risk of autism in a national birth cohort Progress in Neuro-Psychopharmacology and Biological Psychiatry, December 1, 2014    Clinical Article

13 Living SMART — A randomized controlled trial of a guided online course teaching adults with ADHD or sub-clinical ADHD to use smartphones to structure their everyday life Internet Interventions, December 5, 2014    Clinical Article

14 Antipsychotic treatment and mortality in schizophrenia Schizophrenia Bulletin, December 16, 2014    Clinical Article

15 Blood manganese levels in relation to comorbid behavioral and emotional problems in children with attention-deficit/hyperactivity disorder Psychiatry Research, November 4, 2014    Clinical Article

16 Aripiprazole versus quetiapine in treatment-resistant obsessive–compulsive disorder: A double-blind clinical trial Therapeutic Advances in Psychopharmacology, December 24, 2014    Clinical Article
Exclusive Author Commentary

17 Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials JAMA Psychiatry, October 22, 2014    Evidence Based Medicine    Clinical Article

18 Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder JAMA Psychiatry, December 11, 2014    Evidence Based Medicine    Clinical Article

19 Cognitive effects of statin medications CNS Drugs, February 18, 2014    Clinical Article

20 Low serum levels of vitamin D are associated with post-stroke depression European Journal of Neurology, December 9, 2014    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List